quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 15, 2026

Morgan Stanley outlines path to $10T-plus client assets and sustained 20%+ ROTCE through market cycles

View original at seekingalpha.com
Morgan Stanley outlines path to $10T-plus client assets and sustained 20%+ ROTCE through market cycles Earnings Call Insights: Morgan Stanley (MS) Q4 2025 MANAGEMENT VIEW * CEO Ted Pick opened with, "In 2025, the U.S…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2025 was an exceptional year for Morgan Stanley marked by deliberate execution of strategy

    80% confidence

  • Morgan Stanley is monetizing capital markets green shoots across investment banking and markets verticals, and scaling asset inflows and transaction activity across wealth businesses

    80% confidence

  • Wealth Management margin expansion driven by building out fee-based revenues and fee-based assets, plus efficiency through technology

    80% confidence

  • No philosophical frame shift on targets; firm now has confidence to discuss performance in more challenging environments with ability to still generate 17.5% ROTCE with earnings below $8

    80% confidence

  • For remainder of 2026, assuming current forward curve, incremental loan growth and deposit mix projections, NII expected to continue to trend higher

    80% confidence

  • Targets will be revisited later in the year; if clearly passed through, they will consider taking them higher

    80% confidence

  • Morgan Stanley gained 100 basis points of wallet share in Institutional Securities

    80% confidence

  • In 2025, the U.S. economy proved resilient with well-capitalized corporates and higher-end consumers driving the economy forward

    80% confidence

  • Growth plans embed the increasing adoption of AI tools throughout the enterprise and inside client base

    80% confidence

  • This is not the time to overreach, emphasizing disciplined approach to capital deployment and M&A

    80% confidence

  • If there are lower asset prices due to drawdown, economic blip, or geopolitical event, there could be lower levels of performance

    80% confidence

  • Looking ahead to Q1 2026, NII expected to remain roughly flat quarter-over-quarter as higher average sweeps and lending balances offset the full impact of two rate cuts in Q4

    80% confidence

  • Equitization of markets around the world is underway; institutional trading wallet could continue to grow 5-10% per annum

    80% confidence

  • 2026 starts with the tailwinds of constructive fiscal policy and easier monetary policy

    80% confidence

  • If environment is welcoming, firm expects to execute at or above firmwide goals as in 2025; when backdrop is more challenged, aim to achieve higher lows

    80% confidence

  • Firm is focused on compounding earnings through the cycle rather than overreaching

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Morgan Stanley outlines path to $10T-plus client assets and sustained 20%+ ROTCE through market cycles — Source | Via News | pt.VIA.NEWS